- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Fut8 Sugar coating immuno oncology
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Novel therapy for drug-resistant cancers
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Selective JAK inhibition: mimicking SOCS activity
- Targeting minor class splicing
- Treating Epstein-Barr virus associated malignancies
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Anne Voss
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Marnie Blewitt
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Bob Anderson
- Dr Brad Sleebs
- Dr Diana Hansen
- Dr Drew Berry
- Dr Emma Josefsson
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Hélène Jousset Sabroux
- Dr Ian Majewski
- Dr Ian Street
- Dr Jacqui Gulbis
- Dr James Vince
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kate Sutherland
- Dr Kelly Rogers
- Dr Leanne Robinson
- Dr Leigh Coultas
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Misty Jenkins
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rhys Allan
- Dr Samir Taoudi
- Dr Sant-Rayn Pasricha
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Stephen Wilcox
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Ms Samantha Ludolf
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jason Tye-Din
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- 6 cysteine proteins key mediators between malaria parasites and human host
- A balancing act of immunity: autoimmunity versus malignancies
- Activating https://www.wehi.edu.au/node/add/individual-student-research-page#Parkin to treat Parkinson’s disease
- Analysing single cell technologies to understand breast cancer
- Bioinformatics methods for detecting and making sense of somatic genomic rearrangements
- Characterising new regulators in inflammatory signalling pathways
- Computational melanoma genomics
- Control of human lymphocyte cell expansion in complex immune diseases
- Deciphering biophysical changes in red blood cell membrane during malaria parasite infection
- Deciphering the signalling functions of pseudokinases
- Deep profiling of blood cancers during targeted therapy
- Determining the mechanism of type I cytokine receptor triggering
- Differential expression analysis of RNA-seq using multivariate variance modelling
- Discovering new genetic causes of primary antibody deficiencies
- Discovery of novel drug combinations for the treatment of bowel cancer
- Drug targets and compounds that block growth of malaria parasites
- Effects of nutrition on immunity and infection in Asia and Africa
- Enabling deubiquitinase drug discovery
- Epigenetic drivers of immune cell function
- Epigenetic regulation of systemic iron homeostasis
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Fatal attraction: how apoptotic pore assembly is governed during mitochondrial cell death
- Genomic instability and the immune microenvironment in lung cancer
- How do T lymphocytes decide their fate?
- How the epigenetic regulator SMCHD1 works and how to target it to treat disease
- Human lung protective immunity to tuberculosis: host-environment systems biology
- Human monoclonal antibodies against malaria infection
- Identifying novel treatment options for ovarian carcinosarcoma
- Inflammasome activation in autoinflammatory disease
- Investigating mechanisms of cell death and survival using zebrafish
- Investigating microbial natural products with anti-protozoal activity
- Investigating the role of mutant p53 in cancer
- Investigating the role of platelets in motor neuron disease
- Mapping DNA repair networks in cancer
- Molecular mechanisms controlling embryonic lung progenitor cells
- Nanobodies against malaria
- Neutrophil heterogeneity in inflammation
- New approaches to treat cancer and inflammatory disease using the ubiquitin system
- Next generation CRISPR screens using iPSC
- Novel cell death and inflammatory modulators in lupus
- Programming T cells to defend against infections
- Restraining cytokine-receptor signalling in myeloproliferative neoplasms
- Screening for regulators of jumping genes
- Statistical analysis of genome-wide chromatin organisation using Hi-C
- Statistical analysis of trapped-ion-mobility time-of-flight mass spectrometry proteomics data
- Structure and function of E3 ubiquitin ligases
- Target identification of potent antimalarial agents
- The mitochondrial TOM complex in neurodegenerative disease
- The molecular mechanisms underlying Kir4.1 activity in gliomas
- The role of differential splicing in the genesis of breast cancer
- Uncovering the roles of long non-coding RNAs in human bowel cancer
- Understanding malaria infection dynamics
- Understanding the function of the E3 ligase Parkin in Parkinson’s disease
- Understanding the molecular basis of chromosome instability in gastric cancer
- Utilising pre-clinical models to discover novel therapies for tuberculosis
- School resources
- Frequently asked questions
- Student profiles
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Primary immunodeficiency

Our immune system normally prevents infection. In immunodeficiency, one or more components of the immune system are lacking. This puts people at risk of life-threating infections.
Our research seeks to discover how immunodeficiencies occur, with the goals of improving diagnosis of immunodeficiencies and how they are treated.

Our immunodeficiency research
Our immunology researchers aim to understand how immunodeficiencies occur, and how they can be better treated. Our laboratory and clinical research efforts include:
- Defining how the immune system normally develops and functions, to understand what goes wrong in immunodeficiencies.
- Discovering the genetic and immune changes that cause common variable immunodeficiency, the most common inherited (primary) immunodeficiency in Australia and worldwide.
- Investigating HIV, a major cause of immunodeficiency worldwide.
What are immunodeficiencies?
Immunodeficiencies are a broad class of conditions where one or more components of the immune system are missing. A person with an immunodeficiency has trouble fighting infections. They may contract more illnesses than other people, and may become infected with microbes that do not normally cause disease in humans.
Primary and secondary immunodeficiency
When someone is born lacking a component of the immune system, it is termed ‘primary immunodeficiency’.
Secondary immunodeficiency describes immunodeficiencies arising as the result of another event such as HIV infection or taking immune suppressing medication.
The Immune Deficiencies Foundation Australia provides information and support for people with immunodeficiencies, their carers and relatives.
What causes primary immunodeficiency?
Many primary immunodeficiencies are caused by changes in the genes that contribute to immune cell development and function. This means they can be passed from parents to a child, or can occur frequently in an extended family.
What is common variable immunodeficiency?
Common variable immunodeficiency (CVID) is the most common primary immunodeficiency, both in Australia and worldwide. It is estimated that approximately one in 10,000 Australians have CVID.
People with CVID have problems making antibodies, which are important in fighting infections and building immune protection. Low levels of antibodies put people with CVID at risk of recurrent bacterial infections. These people are also unable to develop a normal immune response to vaccines.
Diagnosing CVID is difficult and requires exclusion of other primary immunodeficiencies. As symptoms of CVID can be quite different between people, many people with this condition are not diagnosed until they are adults.
What causes CVID?
CVID appears to be caused by faulty genes. However, it appears there are many different genes that can contribute to CVID. Only in a few cases have the gene changes causing CVID been identified. For most people, the underlying cause of CVID is not known.
Our research into CVID aims to find the underlying cause of CVID. To do this we need help from people with CVID, as well as people with another immune deficiency called X-linked agammaglobulinemia (XLA). Find out more about our study into the causes of CVID.
CVID and autoimmune disease
Around a quarter of people with CVID have autoimmune diseases. This suggests that the cause of CVID could be part of a broader problem with the control of the immune system, where appropriate immune responses to microbes are stifled, but harmful attacks on normal body tissues occur.
How is CVID treated?
Once diagnosed, the only treatment for CVID is to receive regular and lifelong treatment with antibodies (an important product of donated blood) from healthy donors. Even with this ‘antibody replacement therapy’ people with CVID frequently experience serious complications, including autoimmune disease. Antibody replacement therapy also cannot entirely prevent life-threating infections.
Researchers:
Super Content:
Catch up with this public talk discussing the latest research, discoveries and treatments for coeliac disease, lupus and primary immune deficiencies.
If you are aged between 18 and 80 and have been diagnosed with common variable immunodeficiency (CVID) or X-linked agammaglobulinemia (XLA), we invite you to contact our research team.
Frank Macfarlane Burnet was awarded the Nobel Prize in 1960 and is widely acknowledged as the founder of modern immunology. This animation was created to commemorate the 50th anniversary of Burnet's landmark discovery.
Our researchers have defined for the first time how the size of the immune response is controlled during infection, or in response to vaccination.